Form 4: Acrivon Therapeutics COO Acquires Stock Options

Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, acquired stock options for 140,540 shares on March 1, 2025.

Summary

• Eric Devroe, the Chief Operating Officer of Acrivon Therapeutics, Inc. [ACRV], filed a Form 4 on March 4, 2025.
• The filing reports a transaction that occurred on March 1, 2025, where Devroe acquired stock options for 140,540 shares of common stock at an exercise price of $5.31.
• These options vest over time, with 25% vesting on March 1, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continuous service.
• The options expire on February 28, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices and aligns management interests with shareholders.

Positives

• The acquisition of stock options by the COO aligns his interests with those of the shareholders, incentivizing him to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used to align management's interests with shareholder value.
• Companies like Amgen, Gilead, and Regeneron also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term commitment and performance.

Stakeholder Impact

• The stock option grant incentivizes the COO to improve company performance, potentially benefiting shareholders.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates